1. Home
  2. Medical News
  3. Cardiology
advertisement

Survodutide Meets CV Safety Criterion in SYNCHRONIZE-CVOT

Illustrated heart with steady rhythm trace representing cardiovascular safety assessment of survodutide in adults with
11/19/2026

Key Takeaways

  • Among adults with obesity and established cardiovascular disease or elevated cardiovascular risk, pooled survodutide met the prespecified cardiovascular noninferiority criterion versus placebo.
  • Nausea occurred in 48% of participants receiving survodutide 3.6 mg and 49% receiving 6.0 mg, versus 12.1% receiving placebo.
  • Gastrointestinal adverse events caused more treatment discontinuations with survodutide than with placebo.
  • Serious and fatal adverse events were reported at broadly similar rates across groups.
Survodutide, a dual glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, raises a cardiovascular safety question for adults receiving treatment for obesity. Cardiovascular risk is especially relevant in those with existing disease or other risk factors. Investigators compared the treatment with placebo to assess that risk.

Investigators conducted the SYNCHRONIZE-CVOT trial, a global, event-driven, double-blind, randomized, placebo-controlled phase 3 cardiovascular safety trial. They randomized 5,530 participants; 5,507 received treatment.

Eligible adults had a body mass index (BMI) of at least 27 kg/m² and established cardiovascular disease or at least two obesity complications or cardiovascular risk factors. Participants with chronic kidney disease needed a BMI of at least 30 kg/m².

Participants were allocated equally to once-weekly subcutaneous survodutide, up-titrated to 3.6 mg or 6.0 mg, or placebo. The primary analysis pooled active doses among randomized participants who received treatment. Its treatment-regimen estimand assessed outcomes regardless of early treatment discontinuation or temporary stops.

The primary composite comprised cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, ischemia-related coronary revascularization, or a heart failure event. Noninferiority required the upper bound of the two-sided 95% confidence interval (CI) for the pooled-dose hazard ratio (HR) to be below 1.65.

The primary composite occurred in 136/3,671 participants (3.7%) receiving pooled survodutide and 76/1,836 (4.1%) receiving placebo. The HR was 0.89 (95% CI 0.67–1.18); p<0.0001 was for noninferiority against the prespecified margin, not for superiority.

Median time in the study was 22.0 months, which does not describe time maintained on assigned treatment. Overall adverse events, including nausea and vomiting, were more frequent with survodutide. Serious and fatal adverse events occurred at broadly similar rates across groups.

Gastrointestinal adverse events led to treatment discontinuation in 354/1,836 participants (19.3%) receiving survodutide 3.6 mg, 381/1,835 (20.8%) receiving 6.0 mg, and 34/1,836 (1.9%) receiving placebo. These dose-specific tolerability findings differ from the pooled cardiovascular comparison.

Noninferiority applies to the specified composite in the enrolled population and to the active doses pooled together. It does not establish cardiovascular superiority or fewer events with survodutide. Dose-specific adverse-event observations do not establish dose-specific cardiovascular effects.

Investigators concluded that survodutide was not associated with increased risk of the primary cardiovascular composite versus placebo in adults with obesity and established cardiovascular disease, chronic kidney disease, or higher cardiovascular risk.

Clinician Questions

What qualified as a heart failure event in the SYNCHRONIZE-CVOT cardiovascular endpoint?

For adults with obesity assessed in the survodutide cardiovascular safety trial, a qualifying event could be a heart failure hospitalization, an emergency department or urgent-care visit, or an urgent outpatient heart failure visit.

How did treatment persistence compare between survodutide and placebo at study closeout in adults with obesity?

In SYNCHRONIZE-CVOT, slightly more than half of adults in each survodutide dose group and the placebo group remained on assigned treatment until closeout, with broadly comparable proportions. This differs from time spent in the study and does not establish uninterrupted medication use.

This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free